摘要
目的分析在治疗非瓣膜性心房颤动合并急性脑梗死时应用脑心通联合华法林的临床疗效。方法随机选择2018年5月至2019年5月期间本院收治的76例非瓣膜性心房颤动合并急性脑梗死患者当作研究对象,并根据病例单双号将其分为治疗A组(华法林治疗)与治疗B组(脑心通联合华法林治疗),每组各38例。比较两组的治疗效果。结果治疗B组的总有效率显著高于治疗A组(P<0.05);治疗后,治疗B组的NIHSS评分与FIB均显著低于治疗A组(P<0.05),且治疗B组的TT、PT及APTT均显著长于治疗A组(P<0.05);治疗B组的不良反应发生率与脑梗死复发率均显著低于治疗A组(P<0.05)。结论对于非瓣膜性心房颤动合并急性脑梗死患者而言,脑心通联合华法林具有更佳的临床疗效,可有效改善患者的神经功能,预防脑梗死复发。
Objective To investigate the clinical effect of Naoxintong Capsule combined with warfarin in the treatment of non-valvular atrial fibrillation with acute cerebral infarction.Methods A total of 76 patients with non-valvular atrial fibrillation and acute cerebral infarction who were admitted to our hospital from May 2018 to May 2019 were enrolled as subjects,and according to the odd or even number of medical records,the patients were divided into treatment group A(treated with warfarin)and treatment group B(treated with Naoxintong Capsule combined with warfarin),with 38 patients in each group.Treatment outcome was compared between the two groups.Results Treatment group B had a significantly higher overall response rate than treatment group A(P<0.05).Compared with treatment group A after treatment,treatment group B had significantly lower NIHSS score and fibrinogen(P<0.05)and significantly longer thrombin time,prothrombin time,and activated partial thromboplastin time(P<0.05).Treatment group B had significantly lower incidence rate of adverse events and recurrence rate of cerebral infarction than treatment group A(P<0.05).Conclusion Naoxintong Capsule combined with warfarin has a good clinical effect in the treatment of patients with non-valvular atrial fibrillation and acute cerebral infarction and can effectively improve patient’s neurological function and prevent the recurrence of cerebral infarction.
作者
陈超
CHEN Chao(Fujian Provincial Hospital,Fuzhou 350001,China)
出处
《心血管病防治知识（学术版）》
2020年第19期11-13,共3页
Prevention and Treatment of Cardiovascular Disease
关键词
脑心通
华法林
非瓣膜性心房颤动
急性脑梗死
Naoxintong Capsule
Warfarin
Non-valvular atrial fibrillation
Acute cerebral infarction
